

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

SMS-SAN

RRID:CVCL_7136

Type: Cell Line

Proper Citation

RRID:CVCL_7136

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_7136

Proper Citation: RRID:CVCL_7136

Description: Cell line SMS-SAN is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Neuroblastoma

Defining Citation: [PMID:3456456](#), [PMID:7037175](#), [PMID:11507071](#), [PMID:15390183](#), [PMID:15892104](#), [PMID:16822308](#), [PMID:18724359](#), [PMID:23202128](#), [PMID:24792489](#), [PMID:28350380](#)

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SMS-SAN

Synonyms: sms-SAN, SMS SAN

Cross References: cancercellines:CVCL_7136, Cosmic:717428, Cosmic:848933, Cosmic:1019951, Cosmic:1162008, Cosmic:1890107, GEO:GSM2371261, GEO:GSM2394374, GEO:GSM3145589, GEO:GSM3145731, Wikidata:Q54954998

ID: CVCL_7136

Record Creation Time: 20220427T221550+0000

Record Last Update: 20260913T010053+0000

Ratings and Alerts

No rating or validation information has been found for SMS-SAN.

No alerts have been found for SMS-SAN.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Sehgal P, et al. (2025) NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomas. *Cell reports*, 44(8), 116099.

Giudice AM, et al. (2025) D3-GPC2-Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(24), 5276.

Pascual-Pasto G, et al. (2024) Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(16), 3578.

Radosevich MT, et al. (2023) Antigen density quantification of cell-surface immunotherapy targets by flow cytometry: Multi-antigen assay of neuroblastoma bone marrow metastasis. *STAR protocols*, 4(4), 102709.

Lee JY, et al. (2023) Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma. *Cell reports. Medicine*, 4(6), 101091.

Heitzeneder S, et al. (2022) GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. *Cancer cell*, 40(1), 53.

Buongervino S, et al. (2021) Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization. *Molecular cancer therapeutics*, 20(11), 2228.

Raman S, et al. (2021) A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. *Cell reports. Medicine*, 2(7), 100344.

Bosse KR, et al. (2017) Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. *Cancer cell*, 32(3), 295.